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Background and rationale
In an effort to promote vaccine research and develop-
ment of enteric vaccines, including cholera, typhoid fe-
ver, and rotavirus vaccines and to address the challenges 
for their future implementation, the WHO Initiative for 
Vaccine Research hosted a one-day Satellite Sympo-
sium dedicated to addressing the opportunities to use 
the licensed vaccines against cholera and typhoid fe-
ver and to consider the challenges which remain for in-
troduction of rotavirus vaccine, including clinical trials 
in developing-country settings. The Bill and Melinda 
Gates Foundation graciously provided US$ 50,000 to 
organize the Satellite Symposium. 
  The Symposium was followed by a three-day Global 
Vaccine Research Forum, which also included a session 
on the other two important enteric vaccines against en-
terotoxigenic Escherichia coli and Shigella. The Forum 
brought together a world-wide selection of top research-
ers and scientists and served as a forum for the partners 
of GAVI (the Global Alliance for Vaccines and Immu-
nization) to discuss vaccine research and development 
issues and to update research agenda. Moreover, both 
the meetings provided an opportunity for discussion of 
broader issues of vaccine policy and implementation. 
Goals, objectives, and activities  
Although diarrhoeal mortality, globally, is observed to 
be on the decrease, it is well-recognized that the vast 
bulk of morbidity and mortality of the estimated annual 
1.9 million deaths is borne by infants and young chil-
dren living in developing countries. The Symposium 
addressed the challenges and opportunities for the ef-
fective implementation of these vaccines in the regions 
where they are most needed.
  Currently, two vaccines are licensed for cholera, but 
are not yet readily used in the areas considered endemic 
for cholera, nor in children who are largely affected by 
the disease. Two recent studies have demonstrated that 
(a) cholera vaccine can be administered in mass immu-
nization campaigns in areas where cholera is endemic 
with good protective effects and (b) that there appears to 
be good herd protection in vaccinated populations and 
non-vaccinated individuals. The remaining challenges 
include identifying and overcoming the obstacles to im-
plementation of the vaccines in these settings. Similarly, 
the typhoid fever vaccines are licensed and have been 
proven to be effective in preventing the disease and can 
be administered in school-age populations with good 
protection given. 
  The present state of development of rotavirus vac-
cines indicates an urgent need to increase the global ca-
pacity to conduct multiple clinical trials in developing 
countries, particularly in Africa and Asia. These trials 
will need to evaluate safety, immunogenicity, and effi-
cacy of the vaccine candidates in different populations 
and geographical areas which differ significantly in epi-
demiology of the virus and viral strain diversity and in 
the social, health, and economical background of the 
population—all of which may have a significant impact 
on final efficacy results.  
  The agenda of the Symposium (attached) included 
different sessions focused on different enteric vaccines, 
which allowed for discussion of priority issues which 
have been identified as major obstacles for the imple-
mentation of vaccines against cholera and typhoid fever 
and the introduction of rotavirus vaccines.  
MEETING REPORT
Correspondence and reprint requests should be addressed to:
Prof. Duncan Steele
Initiative for Vaccine Research/RPD 
Department of Immunization, Vaccines and Biologicals 
World Health Organisation 
20 Avenue Appia 
CH-1211 Geneva 27 
Switzerland
Tel: +41 22 791 3752, Fax: +41 22 791 4860
Email: steeled@who.intThe participants of the Satellite Symposium were pro-
vided with an opportunity to attend all other sessions of 
the Forum to interact and share their experiences with 
experts working on other infectious diseases or areas. 
The linking of the Symposium with the Global Vaccine 
Research Forum has, thus, provided an ideal forum for 
cross-field interactions, exchange of information, and 
sharing of experiences between scientists against other 
priority infectious diseases, such as HIV, tuberculosis, 
malaria, and other infections, including enterotoxigenic 
E. coli and Shigella, with high-level participation from 
experts in the field of vaccines, including that from de-
veloping countries. 
Accomplishments and outcomes of the Symposium 
The focus of the Symposium was typhoid fever and 
cholera (for which licensed vaccines have been available 
for a number of years), and rotavirus. The presentations 
addressed the question whether introduction plans for 
rotavirus, typhoid, and cholera vaccines are credible in-
vestment cases for developing countries. 
The main conclusions of the Symposium were as follows: 
•  There is a global need for enteric vaccines, and 
rotavirus, typhoid, and cholera are all credible in-
vestment cases for developing countries; these 
investments should be based on the burden of dis-
ease, cost-effectiveness estimates, demonstration 
projects, and availability and financing of vaccines. 
•  As for rotavirus vaccines—for which an Acceler-
ated Development and Introduction Plan (ADIP) 
already exists—a similar focused investment could 
be considered for typhoid vaccines. 
•  Good progress has been achieved with the rota-
virus ADIP but it is very important to generate good 
rotavirus-efficacy data for Africa and Asia in addi-
tion to the existing data in Latin America, to assess the 
global performance of the new vaccines properly. 
•  Cholera vaccines need a double approach for high-
endemic settings and control of epidemics. There is 
an urgent need for both recommendations on how to 
use the vaccine and on the question of the establish-
ment of a stockpile. 
For enteric vaccines in general, the following few hur-
dles should be overcome before wider use: 
•  More effective communication of the importance 
of enteric infections and the potential of vaccines to 
save lives in a cost-effective manner. 
•  Communication of the obvious—that vaccines are 
complements, and not replacements or threats, to 
other useful control methods. 
•  Advocacy that the search for the ‘ideal’ should not 
be the enemy of the ‘good’ and to use existing pro-
ducts while promoting improvements in existing 
vaccine formulations and research and development 
(R&D) into new vaccines. 
•  Definition of the complexities and provision of so-
lutions to ‘challenges’, which are not ‘insurmount-
able problems’. 
More specifically, for typhoid fever vaccines 
•  Since antibiotic resistance is rising, and water and 
sanitation improvement is a long-term goal, vacci-
nes are the only viable intervention to control typhoid 
in the short and medium terms. 
•  Typhoid fever causes significant mortality/morbi-
dity and major direct and indirect economic losses; 
large-scale introduction of a typhoid vaccine is an 
opportunity to make a significant contribution to 
the Millennium Development Goals (MDGs) and to 
the objectives of GAVI. 
•  There are safe and effective, available, licensed 
vaccines; vaccination is feasible, acceptable, and 
affordable. 
•  There is a cost-competitive supply of vaccines, and 
there are ways to rationally vaccinate populations 
at highest risk in a financially-sustainable way. 
•  There is a perceived value and interest on the part of 
country-level decision-makers. 
More specifically, for rotavirus vaccines 
•  There is a need for safe, efficacious, and affordable 
vaccines. Rotavirus vaccines for the industrialized 
world will be available soon, but will a live, oral ro-
tavirus vaccine work in infants in developing coun-
tries where it is needed most? This remains a key 
question. 
•  In addition to the two most advanced candidates, 
there are multiple additional vaccine candidates 
and producers interested in manufacturing rotavirus 
vaccines in developing countries. 
•  In view of the above, it is important that national re-
gulatory authorities in developing countries contin-
ue to be strengthened by WHO and that work conti-
nues on standardization of quality control and safety 
(production process, facility, candidate strain…). 
More specifically, for cholera vaccines 
•  When should cholera vaccines be used?: (a) in high-
endemic settings, and/or (b) as adjuncts for epidemic 
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WHO. 
•  A recently-published study in Mozambique showed 
that vaccine was highly effective against clinically 
significant cholera in an urban African population 
with a high prevalence of HIV infection. 
•  The establishment of a cholera vaccine stockpile 
has recently been discussed. However, there are still 
many challenges for the use of vaccines in disaster 
and outbreak situations. 
•  There is a need for WHO recommendations on how 
to use cholera vaccines. 
Both Satellite Symposium and main Global Vaccine Re-
search Forum were very well-attended with more than 
50 and 150 participants respectively from all regions 
and representing all stakeholders of the fields of R&D 
of immunization and vaccine. 
  Extensive media coverage organized around both 
events allowed for effective advocacy and dissemination 
of key messages. 
  The report of the Symposium and Global Vaccine 
Research Forum has been completed and is being print-
ed at WHO. It will be disseminated widely in the R&D 
of immunization and vaccine as hard copies and be 
posted on the Initiative for Vaccine Research website. 
Summary of the Symposium  
The WHO Initiative for Vaccine Research and Depart-
ment of Immunization, Vaccines and Biologicals plans 
to act on the conclusions and recommendations of the 
Symposium and notably in the following areas: 
•  In collaboration with GAVI partners, consider the 
opportunity for an investment case for typhoid vac-
cines. 
•  Collaborate with the WHO Global Cholera Task 
Force on the revision of recommendations on how 
to use the vaccines and on the establishment of a 
stockpile of potential vaccines. 
•  More effectively communicate the potential of vac-
cines against enteric infections. 
•  Advocate for the generation of credible rotavirus-ef-
ficacy data for Africa and Asia. 
•  Promote the development of more upstream rotavi-
rus vaccine candidates by developing-country manu-
facturers. 
•  Continue to strengthen national regulatory authori-
ties in developing countries for the approval and 
monitoring of vaccine clinical trials and the registra-
tion of new vaccines. 
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AGENDA 
Moderator:    Jan Holmgren 
Rapporteur:   Duncan Steele 
08:00-09:00   Registration 
09:00-09:30   Global need for vaccines against enteric and 
  diarrhoeal diseases in the developing world  —  Jan Holmgren 
Typhoid Fever Immunization—From Evidence Base to Implementation  —  John Clemens 
09:30-10:00   Control of typhoid fever in Pakistan through immunization  —   Anita Zaidi 
10:00-10:30   The investment case of typhoid fever vaccination  —   Luis Jodar 
10:30-10:45   Experiences with live oral typhoid vaccines  —   Mike Levine 
10:45-11:00   Discussion 
11:00-11:20   Coffee break 
Cholera Vaccines—A Public Health Tool?  —   Ann-Mari Svennerholm 
11:20-11:50   Cholera immunization—the Mozambique experience  —   Marcelino Lucas 
11:50-12:20   When should cholera vaccines be used?   —  Claire-Lise Chaignat 
12:20-12:50   Discussion 
12:50-14:00   Lunch 
Rotavirus Vaccines—What Remains to be Done?   —  Mike Levine 
14:00-14:30   The hurdles and challenges ahead for rotavirus vaccines  —   Joe Bresee 
14:30-14:45    Clinical trials for infants in developing countries   —   Duncan Steele 
14:45-15.00    Challenges to oral delivery of vaccines   —  Martin Friede 
15:00-15:30    Discussion 
15:30-16:30    Summary and wrap-up  —  Jan Holmgren 
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